研究者業績
基本情報
経歴
3-
2021年4月 - 現在
-
2020年4月 - 2021年3月
-
- 2019年3月
学歴
1-
1986年4月 - 現在
委員歴
6受賞
13-
2017年5月
-
2016年5月
-
2015年4月
-
2014年5月
-
2013年5月
論文
1237-
Digestion 2025年4月9日INTRODUCTION: Gastrectomy considerably affects the gut microbiome; however, the association between dysbiosis and post-gastrectomy syndrome remains to be explored. This study prospectively explored fecal gut microbiota alterations before and 3 months after gastrectomy, investigating their potential association with weight loss. METHODS: The gut microbiome of 21 patients with gastric cancer scheduled for gastrectomy in April-October 2022 was analyzed using 16S rRNA gene Next-Generation Sequencing. Their microbiome profiles were compared to those of healthy controls. Bacterial taxa demonstrating significant changes were determined using the Linear Discriminant Analysis Effect Size algorithm and further analyzed for their relationship with weight loss in the gastrectomy cohort. RESULTS: Postoperative complications (≥grade 2) were observed in 14.3% of patients. Postoperative weight loss was -10.9%, with the following breakdown: distal (-7.0%), total (-13.5%), and proximal (-14.0%) gastrectomy (P = 0.003). Microbiota analysis demonstrated a significant incline in the abundance of the Streptococcus salivarius group and a decline in Bacteroides uniformis in patients with gastric cancer compared to healthy controls. The S. salivarius group exhibited a further increase, while B. uniformis showed signs of recovery after gastrectomy. Additionally, 5α-reductase gene levels, reported to decrease as several cancers progress, were found to elevate post-surgery. Furthermore, patients experiencing greater weight loss showed a significant reduction in Faecalibacterium prausnitzii levels, while lower serum prealbumin and zinc levels were associated with the abundance of Escherichia coli. CONCLUSION: Gastrectomy significantly alters the gut microbiome. Supporting microbiome health with prebiotics may help alleviate postoperative issues and improve patients' quality of life.
-
DEN open 5(1) e413 2025年4月The new Kyoto guidelines for the management of intraductal papillary mucinous neoplasm (IPMN) provide evidence-based recommendations for the diagnosis and treatment of IPMN. Endoscopic ultrasonography (EUS) is a diagnostic modality with a high spatial resolution that allows detailed observation and obtaining cyst fluid or tissue samples via EUS-guided fine needle aspiration (EUS-FNA). Currently, EUS is an indispensable examination method for the diagnosis of pancreatic diseases. On the other hand, there have been concerns that EUS imaging tends to be highly operator-dependent, and may lack objectivity. Previous guidelines have assigned EUS as an option for patients with worrisome features. However, recent reports indicate that the sensitivity of EUS for the diagnosis of mural nodules (MNs) is more than 90%, comparable or superior to that of contrast-enhanced computed tomography or magnetic resonance cholangiopancreatography. The specific advantages of EUS in the diagnosis of IPMN are: (1) high spatial resolution imaging for the diagnosis of MNs, (2) contrast-enhanced EUS for differentiation of intra-cystic MNs from mucous clots, and (3) pathological diagnosis using EUS-FNA and differential diagnosis of a pancreatic cystic tumor by cystic fluid analysis. In order to utilize EUS in the diagnosis of IPMN, endoscopists are required to have the skills to provide sufficiently objective imaging findings.
-
Journal of hepato-biliary-pancreatic sciences 2025年3月16日PURPOSE: This study aimed to clarify the current treatment status for biliary tract cancers based on data from the National Clinical Database (NCD) in Japan. METHODS: Total 3895 cases of biliary tract cancers registered in the NCD during 2021 were included. We identified the rates of resection, R0 resection, postoperative complications, and incidences of lymph node metastasis for gallbladder carcinoma, perihilar cholangiocarcinoma, distal bile duct carcinoma, and ampullary carcinoma. RESULTS: The number of biliary tract cancers registered in the NCD during 2021 was 3895 (1775 in extrahepatic bile duct carcinoma, 1422 in gallbladder carcinoma, and 698 in ampullary carcinoma). In gallbladder carcinoma, the resection (89.59%) and R0 resection rates (87.99%) were favorable, and the complication rate (6.05%) was lower than that of others. However, the postoperative complication rate could be higher in T3-T4 cases and when extrahepatic bile duct resection was performed concomitantly. Lymph node metastasis was frequently seen in 12.60% at the No. 13a lymph node. In perihilar cholangiocarcinoma, the R0 resection (69.82%) and complication rates (16.75%) were significantly lower and higher, respectively. In distal cholangiocarcinoma and ampullary carcinoma, metastasis was observed in approximately 2% and 10% of the dissected No. 16b1 para-aortic lymph nodes, respectively. In conclusion, although short-term surgical outcomes for biliary tract cancers in Japan might be acceptable, the significantly lower R0 resection and higher complication rates of perihilar cholangiocarcinomas indicate additional challenges for surgeons in the future and should continue to be monitored by the Japanese Society of Hepatobiliary and Pancreatic Surgery.
-
2025年2月21日Feline atopic skin syndrome (FASS) is a chronic inflammatory skin disease characterized by itching and dermatitis. While the relationship between the gut microbiota and atopic dermatitis (AD) has been highlighted, exploring gut-targeted therapies for FASS remain limited. This study aimed to evaluate the effects of a parasynbiotic containing 1-kestose and heat-killed Lactobacillus plantarum FM8 on clinical symptoms and gut microbiota in cats with FASS. Eleven FASS cats were treated with a parasynbiotic containing 1-kestose (400 mg/day) and heat-killed FM8 (2.0 × 1010 CFU/day) for 8 weeks. Clinical symptoms were assessed using the SCORing Feline Allergic Dermatitis (SCORFAD), investigator pruritus score (IPS), and rating of global assessment of improvement (GAI). Fecal microbiota composition was analyzed through 16S rRNA sequencing, with 16 healthy cats serving as controls. Parasynbiotic intervention significantly reduced SCORFAD and IPS scores. GAI scores improved in 10 of 11 cats, with the most severe case maintaining a score of 3. The β-diversity analysis showed no significant differences; however, a trend toward variation was observed between the healthy control cats and the baseline group of FASS cats, as well as between the healthy control cats and post- intervention groups. The abundance of Collinsella stercoris was significantly higher in FASS cats than in healthy controls, and it significantly decreased after parasynbiotic intervention, suggesting potential improvements in gut health and inflammation. This study is the first to demonstrate the potential benefits of parasynbiotic administration in FASS, showing improvements in clinical symptoms and partial modulation of the gut microbiota. These findings highlight parasynbiotic administration as a compelling therapeutic approach for FASS, offering new possibilities for innovative interventions aimed at the gut–skin axis.
-
Microbiology 170(11) 2024年11月21日Recent studies have linked Ruminococcus gnavus to inflammatory bowel disease and Fusobacterium nucleatum to various cancers. Agarooligosaccharides (AOS), derived from the acid hydrolysis of agar, have shown significant inhibitory effects on the growth of R. gnavus and F. nucleatum at concentrations of 0.1 and 0.2%, respectively. RNA sequencing and quantitative reverse-transcription PCR analyses revealed the downregulation of fatty acid biosynthesis genes (fab genes) in these bacteria when exposed to 0.1% AOS. Furthermore, AOS treatment altered the fatty acid composition of R. gnavus cell membranes, increasing medium-chain saturated fatty acids (C8, C10) and C18 fatty acids while reducing long-chain fatty acids (C14, C16). In contrast, no significant growth inhibition was observed in several strains of Bifidobacteria and Lactobacillales at AOS concentrations of 0.2 and 2%, respectively. Co-culture experiments with R. gnavus and Bifidobacterium longum in 0.2% AOS resulted in B. longum dominating the population, constituting over 96% post-incubation. In vivo studies using mice demonstrated a significant reduction in the Lachnospiraceae family, to which R. gnavus belongs, following AOS administration. Quantitative PCR also showed lower levels of the nan gene, potentially associated with immune disorders, in the AOS group. These findings suggest that AOS may introduce a novel concept in prebiotics by selectively inhibiting potentially pathogenic bacteria while preserving beneficial bacteria such as Bifidobacteria and Lactobacillales.
MISC
438-
膵臓 33(6) 902-913 2018年12月自己免疫性膵炎臨床診断基準2011では、限局性膵腫大例の診断にはendoscopic retrograde pancreatography(ERP)は必須である。ERPは昨今施行されることが少なくなり、限局性膵腫大例をmagnetic resonance cholangiopancreatography所見や超音波内視鏡下穿刺吸引法による癌の否定所見などにより、ERPなしでも診断できるプロセスを策定することが、厚生労働科学研究費補助金(難治性疾患等政策研究事業)「IgG4関連疾患の診断基準並びに治療指針の確立を目指す研究」班より提案された。同消化器疾患分科会で自己免疫性膵炎臨床診断基準2011改訂案を作成し、日本膵臓学会自己免疫性膵炎分科会との合同会議、公聴会にて審議し、決定された最終案に対してパブリックコメントを求めた後、合同会議最終版を自己免疫性膵炎臨床診断基準2018公表版とした。(著者抄録)
-
J Gastroenterol Hepatol. 2017年8月 査読有り
-
GASTROENTEROLOGY 152(5) S1162-S1162 2017年4月0
-
GASTROENTEROLOGY 152(5) S147-S147 2017年4月
-
膵臓 32(4) 714-726 2017年<p>膵石症の一次治療に関する全国調査で125施設1834例(男1479,女355)を集計した.ESWL 103例(5.6%),ESWLと内視鏡併用446例(24.3%),内視鏡261例(14.2%),外科治療167例(9.1%),その他358例(19.5%),無治療499例(27.2%)であった.症状消失率はESWL(内視鏡治療併用を含む)85.7%,内視鏡単独80.8%,外科治療92.8%と外科治療で高かった.早期偶発症はESWL 8.0%,内視鏡単独4.5%,外科治療27.1%,後期偶発症はESWL 1.7%,内視鏡単独2.5%,外科治療8.2%と外科治療で多かった.外科治療移行率ESWL 14.6%,内視鏡単独16.0%,外科治療再手術率6.7%と外科治療で少なかった.専門施設ではESWLと内視鏡併用治療は成績良好で安全に行われていたが,外科治療移行例があり,膵臓専門の外科との連携が必要である.</p>
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 31 242-242 2016年11月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 31 217-217 2016年11月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 31 379-379 2016年11月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 31 315-315 2016年11月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 31 367-368 2016年11月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 31 299-300 2016年11月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 31 96-96 2016年11月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 31 58-58 2016年11月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 31 424-425 2016年11月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 31 256-256 2016年11月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 31 357-357 2016年11月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 31 334-334 2016年11月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 31 300-300 2016年11月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 31 414-414 2016年11月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 31 226-226 2016年11月
-
International Immunopharmacology 39 92-96 2016年10月
-
Journal of Gastroenterology and Hepatology (Australia) 31(7) 1236 2016年7月1日
-
GASTROINTESTINAL ENDOSCOPY 83(5) AB330-AB330 2016年5月
-
GASTROINTESTINAL ENDOSCOPY 83(5) AB357-AB358 2016年5月
-
GASTROINTESTINAL ENDOSCOPY 83(5) AB419-AB419 2016年5月
-
GASTROINTESTINAL ENDOSCOPY 83(5) AB343-AB343 2016年5月
-
GASTROINTESTINAL ENDOSCOPY 83(5) AB375-AB375 2016年5月
-
GASTROINTESTINAL ENDOSCOPY 83(5) AB339-AB339 2016年5月
-
GASTROENTEROLOGY 150(4) S905-S905 2016年4月
-
GASTROENTEROLOGY 150(4) S280-S280 2016年4月
-
GASTROENTEROLOGY 150(4) S1163-S1163 2016年4月
-
GASTROENTEROLOGY 150(4) S413-S413 2016年4月
-
JOURNAL OF CLINICAL ONCOLOGY 34(4) 2016年2月
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 30 248-248 2015年12月
所属学協会
15共同研究・競争的資金等の研究課題
11-
日本学術振興会 科学研究費助成事業 2024年4月 - 2029年3月
-
日本学術振興会 科学研究費助成事業 2024年4月 - 2027年3月
-
日本学術振興会 科学研究費助成事業 2023年4月 - 2026年3月
-
日本学術振興会 科学研究費助成事業 2019年4月 - 2022年3月
-
日本学術振興会 科学研究費助成事業 2018年4月 - 2022年3月